30 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
.
Share-based compensation is classified in the consolidated statement of operations and comprehensive loss as follows:
Three months ended March 31 … and adversely impact our business.
Our workers are classified as either employees or independent contractors, and if employees, as either exempt from overtime
424B3
NAMS
NewAmsterdam Pharma Company NV
19 Apr 24
Prospectus supplement
4:21pm
retirement accounts or other tax deferred accounts;
S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S … or through attribution) 10% or more (by vote or value) of our outstanding Ordinary Shares.
If an entity that is classified as a partnership for U.S
POS AM
NAMS
NewAmsterdam Pharma Company NV
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
or other tax deferred accounts;
S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal income tax … ) 10% or more (by vote or value) of our outstanding Ordinary Shares.
If an entity that is classified as a partnership for U.S. federal income tax
424B3
NAMS
NewAmsterdam Pharma Company NV
12 Mar 24
Prospectus supplement
4:18pm
, partnerships, or other entities or arrangements classified as partnerships for U.S. federal income tax purposes;
regulated investment companies … (by vote or value) of our outstanding Ordinary Shares.
If an entity that is classified as a partnership for U.S. federal income tax purposes holds
POS AM
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
deferred accounts;
S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal income tax purposes … or through attribution) 10% or more (by vote or value) of our outstanding Ordinary Shares.
If an entity that is classified as a partnership for U.S. federal
10-K
e37yyn ka4qp9
28 Feb 24
Annual report
8:00am
424B5
2o38w0enuecb8kibnh
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
06js1wu
13 Feb 24
Prospectus supplement for primary offering
5:19pm
424B3
o6t0ps7qn2juqyisdy
19 Dec 23
Prospectus supplement
4:36pm
F-3
miiqk
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
r9o8v315xv
15 Aug 23
Prospectus supplement
4:52pm
POS AM
t3bys
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
m425ce
7 Aug 23
Research and development expenses
7:24am
424B3
q26i3zj485zwt
9 Jun 23
Prospectus supplement
9:43pm
6-K
EX-99.1
a0ong8l333
9 Jun 23
Current report (foreign)
9:39pm
424B3
exrxu3fkeg
8 Jun 23
Prospectus supplement
5:01pm
424B3
1pvpt9 slm2
6 Jun 23
Prospectus supplement
4:20pm
424B3
ysw46zz4
25 Apr 23
Prospectus supplement
8:14am
POS AM
4zpx94a1
17 Apr 23
Prospectus update (post-effective amendment)
9:09am